Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,412 people get ONTY articles and Market Currents by email alert.
Get email alerts on ONTY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 2, 2013)
-
-
PR Newswire (Mar 29, 2013)
-
PR Newswire (Mar 14, 2013)
-
PR Newswire (Mar 7, 2013)
-
-
PR Newswire (Feb 27, 2013)
-
-
-
-
-
Stock Watch Wednesday, 12 DecemberVFC's Stock House • Wed, Dec 12, 2012
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Oncothyreon: Consider Buying Dips but Beware of VolatilityVFC's Stock House • Wed, Jul 27, 2011
-
-
-
-
-
-
Oncothyreon's Run Indicates the Stock Is Rising Above the RadarVFC's Stock House • Wed, May 18, 2011
-
-
-
-
-
-
-
-
Stock Watch Wednesday, 12 DecemberVFC's Stock House • Wed, Dec 12, 2012
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Weekly Stock Watch, Week Of July 1VFC's Stock House • Mon, Jul 2, 2012
-
PR Newswire (May 9, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Mar 29, 2013)
-
PR Newswire (Mar 14, 2013)
-
PR Newswire (Mar 7, 2013)
-
PR Newswire (Feb 27, 2013)
-
at MarketWatch.com (Dec 19, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Oct 31, 2012)
-
PR Newswire (Sep 5, 2012)
-
PR Newswire (Aug 29, 2012)
-
PR Newswire (Aug 9, 2012)
-
PR Newswire (Aug 8, 2012)
-
PR Newswire (Aug 8, 2012)
-
PR Newswire (Jul 24, 2012)
-
PR Newswire (Jul 5, 2012)
-
PR Newswire (Jun 21, 2012)
ONTY vs. ETF Alternatives
Company Description
Oncothyreon, Inc. is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. Our goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 17, 3:56 PM Oncothyreon (ONTY +0.9%) gets a boost from Wedbush today, as the firm upgrades he stock to Outperform and raises the price target from $2 to $5. Wedbush says that its partner Merck KgA may be successful in negotiating a path to approval for Stimuvax with the existing and anticipated new data from ongoing clinical trials. Merck expects to provide an update on their discussion with regulators in 2013. 1 Comment [Healthcare, On the Move]
- Thursday, May 16, 12:55 PM Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY. 3 Comments [Healthcare, On the Move]
-
Thursday, May 16, 12:51 PM
Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%. 2 Comments [On the Move] -
Thursday, May 9, 5:54 PM
After-hours top gainers, as of 5:30 p.m.: UBNT +10%. UNIS +10%. MCP +7%. WIFI +7%. DAR +6%.
After-hours top losers: ONTY -10%. AL -8%. AIRM -7%. SNTS -6%. TSEM -6%. Comment! [On the Move] - Friday, March 15, 3:08 PM Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation. Comment! [Healthcare, On the Move, Earnings]
- Thursday, March 14, 8:17 AM Oncothyreon (ONTY): Q4 EPS of -$0.12 beats by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Wednesday, January 2, 9:10 AM
Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
Losers: ABT -50%. 6 Comments -
Wednesday, December 19, 2012, 12:45 PM
Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%. Comment! [On the Move] -
Wednesday, December 19, 2012, 9:10 AM
Premarket gainers: PTNR +11%. GM +9%. KCG +8%. RMCF +6%. NBG +6%. VRNG +6%. MLNX +5%.
Losers: ONTY -61%. PLXT -18%. NAV -6%. CYS -6%. 3 Comments [On the Move] - Wednesday, December 19, 2012, 8:39 AM Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR) Comment! [On the Move, Healthcare]
- Wednesday, November 7, 2012, 4:53 PM Oncothyreon (ONTY): Q3 EPS of -$0.15 in-line. (PR) Comment! [Earnings, Healthcare]
- Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Friday, August 24, 2012, 10:38 AM Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise. Comment! [Healthcare, On the Move]
-
Friday, August 24, 2012, 9:10 AM
Premarket gainers: ARUN +14%. MTSL +12%. CPRX +10%. LLY +8%. DSCO +7%. FRO +5%. ONTY +5%.
Losers: ADSK -22%. HMSY -5%. Comment! [On the Move] - Wednesday, August 8, 2012, 12:10 AM Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX Comment! [Earnings]
-
- View all 0 replies
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth. -
-
- View all 0 replies
-
Joseph P. Porter
$ONTY up $0.20+. Must be some kind of record. $CUR up, should be reporting on some of its research soon. - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
l3randonf: Ok, I don't understand why ONTY is trading down today with positive earnings announcement. Why?
-
Joseph P. Porter
$AMD is hanging by a thread on a stop I have in place - strange, since it has had lots of good news lately. $ONTY has been doing well. - View all 0 replies
-
- View all 8 replies
-
-
DaLatin: I learned last time Dahlman slammed RNF it was time 2 buy.Tried again& 10% in 4 days.Taking it as Sequestration noise might push it all down
-
- View all 4 replies
-
djamison: I know !!! Just when I was thinking things were are looking good !!
-
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
-
- View all 0 replies
LATEST REPLIES
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth.
-
-
- View all 1 replies
-
l3randonf: Ok, I don't understand why ONTY is trading down today with positive earnings announcement. Why?
-
- View all 4 replies
-
djamison: I know !!! Just when I was thinking things were are looking good !!
-
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
-
- View all 8 replies
-
-
DaLatin: I learned last time Dahlman slammed RNF it was time 2 buy.Tried again& 10% in 4 days.Taking it as Sequestration noise might push it all down
-
- View all 3 replies
-
-
Perkins Cove: ...leaving 25% MORE on the table....double WOW, lol. But it was good for rule #2 Confidence....grin
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 12 replies
-
-
Michael Kudrna: Good info, thanks. DDC has some massive block purchases lately, something seems up with it. Won't be holding into earnings though
-
Michael Kudrna
Added back to $ONTY partial fills around 6.92, bought on price action, still needs more volume though so keeping a tight leash $$ #KSMT - View all 5 replies
-
-
-
Michael Kudrna
Added to $ONTY on large volume move up, average of 6.74. Short squeeze candidate $$ #KSMT $IWM $SPY - View all 1 replies
-
Michael Kudrna: tightening up stops for 2/3 position...it's not catching more volume yet and cautious of a reversal
-
Michael Kudrna
Short squeeze candidate $ONTY setting up well on a weak market day. Initiated long rental at 6.53 w/room to aggressively trade. $$ #KSMT - View all 13 replies
-
-